Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Research Capital
View:
Post by riverrrow on Jul 16, 2023 1:43pm

Research Capital

How many clients does Research Capital have and how manyTLT shares do those clients hold?  Their clients certainly don't seem to be in any hurry to  push TLT share price upwards.
Comment by Johnandrose22 on Jul 16, 2023 5:04pm
The company's website boasts of "30,000 unique clients across Canada". Not sure how to interpret "unique". John
Comment by Legit62 on Jul 16, 2023 7:09pm
Did some research on them, well recognized company, been in business for years, hopefully just time will tell with us and their analysis, LONG,holding 
Comment by Johnandrose22 on Jul 16, 2023 7:37pm
Their website reports that they have 3 billion under management with 30,000 clients....if my math is correct that averages to a portfolio of 100,000 per client....a relatively respectful but modest sum. Is Research Capital the best we can do? John
Comment by 99942Apophis on Jul 16, 2023 8:22pm
Hi Johnandrose22, 15 years ago I knew a gentleman who appeared regularly on BNN market-call show. As you know they would only take calls on the better known stocks however he and I would discuss off air speculative stocks. My assumption is probably other TV regulars from various Financial Institutions wouldn't be any different then him so I can speculate there must be at least a handful of ...more  
Comment by Legit62 on Jul 16, 2023 8:37pm
My feeling is Research Capital is not going to push our SP higher, the data and BTD along with JV deal will get us higher, but still nice to get someone writing about us, counting the days
Comment by 99942Apophis on Jul 16, 2023 9:38pm
Agree 100 percent Legit62 
Comment by fecats on Jul 16, 2023 8:28pm
Sorry, but I don't understand how you think RC clients can push the share price up 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250